Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine in children with Down syndrome
NCT01084135Phase 2Completed
- Sponsor
- Duke University
- Start
- Nov 2009
- Primary completion
- Feb 2014
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rivastigmine in Down syndrome, sponsored by Duke University. Primary endpoint: Vineland Adaptive Behavior Scales, Second Edition (Survey Interview Form) at 20 weeks. Started Nov 2009; status: completed.
02
Drugs
rivastigmine
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT01084135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01084135.